What SEC filings does Pulse Biosciences, Inc. submit to the SEC?

Pulse Biosciences, Inc. (PLSE) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about PLSE?

A Form 4 for PLSE discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Pulse Biosciences, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for PLSE?

The 10-K is Pulse Biosciences, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all PLSE SEC filings directly on EDGAR?

You can view all historical Pulse Biosciences, Inc. filings on the SEC EDGAR company page for PLSE. Each filing card on this page links directly to the original SEC document.

How often does Pulse Biosciences, Inc. file with the SEC?

Pulse Biosciences, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling PLSE shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

PLSE SEC Filing News — Pulse Biosciences, Inc.

Latest SEC filings for Pulse Biosciences, Inc. (PLSE) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-14.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment c…

Sector: Healthcare Industry: Medical Instruments & Supplies Market Cap: $3.4B CIK: 1625101

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for PLSE currently lean bullish. Of the 20 displayed SEC filing records, 2 carry bullish classifications versus 0 bearish classifications. These labels summarize filing attributes; they are not recommendations, probabilities, or evidence of future price direction. There were 9 insider transactions (Form 4) in this period.

PLSE Filing Activity Snapshot 2026-05-14 — 2026-10-14

Insider Transactions (Form 4)

2 buys vs 0 sells

Net insider buying in this period — more purchases than sales reported.

Largest Form 144 Filing

$100.0K

Teplitsky Liane Rae (Chief Operating Officer) · 2026-09-02

2,025 shares · Form 4

Insider Transactions 9 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 9 filings in this group are Form 4s for Pulse Biosciences, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 9 insider filings shown, the breakdown is 7 compensation award and 2 open-market purchase. 2 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×7: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market purchase ×2: The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Form 4 Open-market purchase Insider Buying 2026-09-02

PLSE insider Teplitsky Liane Rae (Chief Operating Officer) bought 2,025 shares (~$100.0K)

Teplitsky Liane Rae, listed as Chief Operating Officer at PULSE BIOSCIENCES, INC., reported an open-market purchase of 2,025 PLSE shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,024	$48.80	$50.0K
`P`	Open-market purchase	1,001	$49.95	$50.0K

Filing: Form 4 (Insider Transaction) Insider: Teplitsky Liane Rae (Chief Operating Officer) Shares: 2,025 Est. Value: $100.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market purchase Insider Buying 2026-08-28

PLSE insider Teplitsky Liane Rae (Chief Operating Officer) bought 2,070 shares (~$100.0K)

Teplitsky Liane Rae, listed as Chief Operating Officer at PULSE BIOSCIENCES, INC., reported an open-market purchase of 2,070 PLSE shares in a Form 4 filing. Insider buying is often treated as a bullish signal because company insiders are committing their own capital.

The insider bought shares on the open market with their own money. This is the only Form 4 category that requires a discretionary cash outlay at the prevailing price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`P`	Open-market purchase	1,036	$48.23	$50.0K
`P`	Open-market purchase	1,034	$48.35	$50.0K

Filing: Form 4 (Insider Transaction) Insider: Teplitsky Liane Rae (Chief Operating Officer) Shares: 2,070 Est. Value: $100.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-28

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

Teplitsky Liane Rae (Chief Operating Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Restricted Stock Units	200,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	700,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Teplitsky Liane Rae (Chief Operating Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-28

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

Skinner Jon (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	300,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Skinner Jon (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

Zanganeh Mahkam (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	30,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	14,504	—	—

Filing: Form 4 (Insider Transaction) Insider: Zanganeh Mahkam (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

van den Broek Richard (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	30,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	8,423	—	—

Filing: Form 4 (Insider Transaction) Insider: van den Broek Richard (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

DUGGAN ROBERT W (Director, 10% Owner) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	30,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	12,495	—	—

Filing: Form 4 (Insider Transaction) Insider: DUGGAN ROBERT W (Director, 10% Owner)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

Soni Manmeet Singh (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	30,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Soni Manmeet Singh (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-15

PLSE insider Form 4 filed for equity award, exercise, or tax withholding

Sainz Maria (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	30,000	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	3,793	—	—

Filing: Form 4 (Insider Transaction) Insider: Sainz Maria (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 9 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 9 in this period for Pulse Biosciences, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-10-14

PLSE filed 8-K — material company event

PULSE BIOSCIENCES, INC. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.